TLR9 and systemic lupus erythematosus: In addition, HCQ reduces basal production of IFNs (van den Borne et al., 1997) and TLR3 and TLR9 activated (Alves et al., 2017; Hjorton et al., 2018) in PBMC from SLE patients.